Business
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in Acumen’s EBDTM (enhanced brain delivery) program targeted for mid-2027Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m.
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7T0IxEJj0Y5HSLwhPACVvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7T0IxEJj0Y5HSLwhPACVvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Lead clinical candidate IND filing in Acumen’s EBDTM (enhanced brain delivery) program targeted for mid-2027","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. ET","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":501,"olType":false},{"type":"text","content":"NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the first quarter of 2026 and provided a business update.","length":391,"tagName":"p"},{"type":"text","content":"“In the first quarter of 2026 Acumen remained steadfast in the execution of our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD. Topline results are expected late this year and are anticipated to provide important evidence in support of the a...